3rd Quarter - Report
ALEXION PHARMACEUTICALS, INC. for ALEXION PHARMACEUTICALS, INC.
Income
—
Expenses
$306,100
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
TTP TTIP TPA
| Lobbyist | Covered position, as disclosed |
|---|---|
| GREGORY KALBAUGH | — |
| HEIDI L WAGNER | — |
Taxation/Internal Revenue Code TAX
Corporate tax reform Orphan Drug Tax Credit Expiring tax provisions
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEIGH OWANO New | — |
| VANESSA PROCTER | — |
Health Issues HCR
Drug Pricing Creates ACT (REMs) CURES Advancing Hope Act (PRV Reauthorization) ACA Implementation Issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| GREGORY KALBAUGH | — |
| LEIGH OWANO New | — |
| VANESSA PROCTER | — |
| HEIDI L WAGNER | — |
Medicare/Medicaid MMM
CMS Part B DEMO Medicaid Reform; Texas Medicaid Medicare Hospital Inpatient Payment Reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEIGH OWANO New | — |
| VANESSA PROCTER | — |
| HEIDI L WAGNER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.